Decision Records

Why: Minimum Citations

Why: Source Authority Available

Why: Source Authority Available

Why: Source Authority Available

Why: Fix the typographical artifact in the Abstract ('remains is consistent with before mechanistic plausibility can be claimed as clinically demonstrated').; Reconcile manifest-level direction codes with bundle excerpts where discrepancies exist (e.g., Bukhbinder 2026 AD risk finding, Wen 2025 seroprotection rates, Wei 2026 pooled ORs) and flag any retained mism...

Why: Repair the truncated Abstract sentence and the truncated Results paragraph; render complete sentences throughout.; Replace every 'Additional corpus sources included animal/preclinical evidence;' placeholder with the actual study name(s) so that source attribution is auditable at the sentence level.; Reconcile the Singh 2022 representative-statistic assignmen...

Why: Replace the 21x repeated 'Additional corpus sources included animal/preclinical evidence' filler in the Evidence Snapshot with the actual animal/preclinical sources from the corpus (Barinda 2024 systematic review of animal studies; Chevret 2026 honeybee queen model)

Why: Either narrow the title to a single anchor that matches one receipt (e.g., the resistance training + IGF-1/PI3K study alone) or replace bundle:2 with a receipt that actually contains usable findings to support a transcriptomic-contrast signal.; If bundle:2 is retained, obtain a full abstract or full text with extractable endpoints, populations, and effect di...

Why: Rename or reframe the memo so the title matches the actual anchor: either (a) an NR-only memo using bundle:1 as the primary receipt, or (b) a separate metformin+exercise transcriptomic memo using bundle:2 as primary, but not both stitched together.; Remove context bundles 3, 4, and 5 unless they can be tied to the primary anchor by population, intervention,...

Why: Integrity Duplicate

Why: The manuscript requires a complete scope reset

Why: Rewrite the Discussion section to remove the repetitive boilerplate safeguard paragraphs and replace them with a coherent, evidence-integrating argument organized around (a) the within-class tensions identified, (b) the cross-domain synthesis, and (c) the bounded conclusions

Why: Either narrow the title/scope to a cross-domain scoping note about quercetin receipt heterogeneity, or remove the dentin and metabolomics receipts and rebuild the bundle around a coherent quercetin-monotherapy or quercetin-in-diabetes frame.; Re-extract the Antidiabetic Potency (2020) and Health Benefits (2022) receipts to capture actual efficacy or mechanis...

Why: Complete scope reset: The author must decide if the memo is about nematode lifespan or human lung function; these cannot be synthesized into a single 'signal' as currently presented.; Correct the synthesis to accurately reflect that R1 is a positive finding and R2 is a null finding.; Rewrite the title to accurately reflect the actual evidence bundle.

Why: Rename or reframe the title to explicitly signal a cross-domain null-evidence map for metformin across distinct endpoints (cognitive/physical function vs

Why: Correctly characterize R1 as a positive primary result (significant lifespan extension in C

Why: Rename or reframe the title to reflect that this is a synthesis of two unrelated metformin null-result findings (cognitive/physical function in PWH + lung function in DPPOS), rather than implying a unified cross-setting program.; Tighten the Synthesis section to make clear these are two independent null findings in distinct populations and endpoints, not a c...

Why: Reselect receipts to address a single bounded, coherent research signal (e.g., metformin's effect on aging-related endpoints in humans, or metformin's anti-inflammatory mechanisms relevant to lung disease).; Do not misclassify positive findings as null results to manufacture a 'two-nulls' synthesis.; Rename the memo to match the actual anchor compound, popul...

Why: Pick ONE anchor

Why: Align title/topic with receipt evidence; unsupported title anchors: adults, alignment, audit, older, outcomes

Why: Align title/topic with receipt evidence; unsupported title anchors: adults, alignment, audit, older, outcomes

Why: Replace R2 with a second receipt directly measuring metformin effects on physical function or frailty in an older-adult human population, or reclassify the memo to a cross-modality contrast (clinical physical-function null + mechanistic vascular caveat) and rename the title accordingly.; Rewrite the Synthesis section as an integrative argument rather than ve...

Why: Either retitle and reframe as a metformin pharmacogenomics memo where R2 is the anchor and R1 is a secondary context receipt, or remove R2 entirely and rebuild a single-source memo on metformin and physical function in PWH using R1 alone.; If both receipts are retained, they must be presented as a cross-topic contrast (e.g., metformin: functional outcomes vs...

Why: Resubmit with a coherent memo anchored on the actual topic: either (a) a metformin–physical-function–older-adults memo using R2 as the primary receipt plus additional cognitive/physical-function metformin evidence in older adults (without HIV), or (b) a metformin–GDM meta-analysis memo using R1 plus comparator pregnancy-outcome evidence